ClinicalTrials.gg
Active, not recruitingNCT02043158Updated Oct 6, 2026

Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer

An observational study in Ovarian Cancer, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 5 sites in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by M.D. Anderson Cancer Center · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
240
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 78 studies in Ovarian Neoplasms by M.D. Anderson Cancer Center — 15 open to participants now, 31 under way, 1 of them phase 3. Ovarian Neoplasms · M.D. Anderson Cancer Center.

Planned enrollment
8th of 17
240 · median 237
Started
2014
with 2 others
Observational
17 of 78
1 open now
Primary completion
2026-12
later than 2 of 30 live
Registered
35th of 78
by date

Among the 78 studies in Ovarian Neoplasms by M.D. Anderson Cancer Center, this one is the 8th largest by planned enrollment of the 17 observational ones that give a count, is one of 3 that started in 2014, is one of 17 observational ones, reaches primary completion later than 2 of the 30 other live ones, and was the 35th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

15 of the 78 studies in Ovarian Neoplasms by M.D. Anderson Cancer Center are open now, in 5 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Ovarian Neoplasms by M.D. Anderson Cancer Center, or all of them as a file.
02

Study summary

The goal of this research study is to learn about diet and exercise habits, emotions, and social support in the lives of women with ovarian cancer.

Read the detailed description

Study Participation:

If you agree to take part in this study, you will fill out a questionnaire, complete an interview, and information will be collected from your medical record.

For the questionnaire, you will answer questions about your quality of life, mood, social support, stress, diet, lifestyle, and demographic information (such as your age and race). The questionnaire should take about 60-90 minutes to complete. If you prefer to fill out the questionnaire online, 3 separate emails will be sent to your email address. Each email will contain a separate link (the first link will be sent from MD Anderson, the second from University of Arizona for the diet questions, and the third from the University of California Los Angeles [UCLA] for the stress questions).

You will also be asked to measure your waist and your hip with a measuring tape and to record the measurements on the questionnaire.

If you prefer to fill out the questionnaire by paper format, you should mail it back to the research staff. However, the stress questions will need to done by phone. A trained interviewer will ask you questions about the amount of stress you may be having or have had in the past. It should take about 25-30 minutes to complete the interview.

If you are a long-term survivor, you will have an interview by phone that will ask for your opinions about the factors that may have contributed to your survival. This interview will take about 45 minutes to an hour and will be audio-recorded. Your name and identifying information will not be recorded.

Information collected from your medical record will include the status of the disease, if the disease has gotten worse, any treatments you have received, and any side effects you may have had. This information will help researchers learn how specific treatments may affect patients.

If you are already enrolled in a protocol in which you will be having tumor tissue collected for future analysis, the information gathered in those studies will be used together with the data collected for this study to learn if behavioral factors relate to your tumor tissue test results.

Length of Study:

Your study participation will be over after completing the questionnaire and interview.

Other Information:

Before any information is recorded, you will be asked for your permission.

The tape recording will be done by members of the study staff. Your audiotape will be given a code number. No identifying information (such as your name and medical record number) will be recorded on the audiotape.

This is an investigational study.

Up to 240 participants will be enrolled in this multicenter study. Up to 120 will take part at MD Anderson.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • Ovarian Cancer
  • Short term survivors
  • Long term survivors
  • Biobehavioral characteristics
  • Sociodemographic characteristics
  • Questionnaire
  • Survey
  • Interview
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Long term and short term ovarian cancer survivors at the University of Texas MD Anderson Cancer Center in Houston, Texas

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. For the long-term survivor group: alive for at least seven years post-diagnosis.
  2. At least 18 years of age.
  3. Can speak and read English.
  4. diagnosed with stage III-IV ovarian, peritoneal or fallopian tube cancer

Exclusion criteria

Exclusion Criteria:

  1. Are in hospice or about to be referred to hospice within the next 3-6 weeks.
  2. Are not oriented to time, person, or place.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ovarian Cancer Survivors

    Short-term and long-term ovarian cancer survivors

    Behavioral: Questionnaire · Behavioral: Interview

Interventions

  • BehavioralQuestionnaire

    Questionnaire completion asking questions about quality of life, mood, social support, stress, diet, lifestyle, and demographic information. Questionnaire should take about 60-90 minutes to complete.

    Also known as: Survey

  • BehavioralInterview

    Interview asking questions about the amount of stress participant may be having or have had in the past. It should take about 25-30 minutes to complete the interview.

06

What researchers measure

Primary outcomes

  1. Biobehavioral Information Collection in Ovarian Cancer Survivors

    Biobehavioral information collected regarding social support, depressed mood, life stress, quality of life, meaning in life, socioeconomic and relationship status, and lifestyle factors such as exercise and diet, which have been linked with cancer progression and/or survival in cancer patients.

    Time frame: 1 day

07

Study locations

5 sites
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2014 (actual). Primary completion is estimated for Dec 2026, 155 months after the start.

Of 216 non-industry observational studies under Ovarian Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 206. This study's planned 155 months is above that.

Counting every sponsor, half of 268 studies reached it within 61 months; a quarter within 35 and three quarters within 185.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2014
First posted
Jan 23, 2014
StartActual
Jan 16, 2014
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02043158
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Jan 23, 2014
Start date
Jan 16, 2014
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Oct 6, 2026

Study contacts

Eileen H. Shinn, PHD, MS, BA
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion